Benzinga··Bamboo WorksCanSino Rebounds on Meningitis Vaccine Success, But Concentration Risk Looms
CanSino reports 26% growth and profitability rebound on meningitis vaccine success, but faces concentration risk and rising competitive threats in China's declining vaccine market.
CASBFcompetitionSoutheast Asia expansion